RESUMEN
Objective To analyze the influence of different therapeutic environments on stigma of schizophrenia patients. Methods A total of 70 outpatients and 70 inpatients with schizophrenia in remission in Tongde hospital of Zhejiang province were enrolled and investigated by using Brief Psychiatric Rating Scale (BPRS),Positive and Negative Syndrome Scale (PANSS),Treatment Emergent Symptom Scale (TESS)and Clinician's Global Impressions-Severity of Illness Scale (CGI-SI).Results Both outpatients and inpatients had been discriminated and had the situation of stigma and disease concealing.After inpatient treatment,the scores of disease concealing factor and positive effect factor were 2.01 ±0.88 and 1.68 ±0.78 respectively,which were significantly lower than those of outpatients (2.43 ±0.98 and 2.44 ±0.78, respectively,P<0.05 ).Conclusion Outpatient treatment has the influence on reduce stigma and improve the life quality of schizophrenia patients in remission.
RESUMEN
Objective To observe the efficacy and safety of oxcarbazepine combined with selective serotonin re-uptake inhibitor (SSRI) in the treatment of outpatients with agitated depression. Methods Thirty-two outpatients with agitated symptoms meeting CCMD-3 depression criteria were treated with oxcarbazepine combined with SSRI for 8 w: the dosage of oxcarbazepine changed dairy (1st and 2nd d, 0.3 g; 3rd d, 0.6 g; 7th and 8th, 1.2-1.5 g). The efficacy and side effects were assessed by Hamilton depression scale, Hamilton anxiety rating scale and Young manic-state rating scale. Results The mean dosage of oxcarbazepine in 32 patients was (1020±65) mg/d. Their mean effective rate and full remission rate 87.5% and 65.6%,respectively. The mean effective rate and full remission rate 1, 2, 4 and 8 w after the treatment were 28.1% (9/32) and 6.3% (2/32), 37.5% (12/32) and 12.5% (4/32), 46.9% (15/32) and 31.3% (10/32), and 90.6% (29/32) and 65.6% (21/32), respectively. The scores of the above scales 1, 2, 4 and 8 w after the treatment were significantly different with those before the treatment (P<0.05). Phase inversion was not found in these 32 patients. Conclusion The oxcarbazepine combined with SSRI maybe one of the better ways in the treatment of patients with agitated depression.